Prion protein inhibits fast axonal transport through a mechanism involving Casein kinase 2

EMILIANO ZAMPONI; FIAMMA BURATTI; GABRIEL CATALDI; HECTOR HUGO CAICEDO; YUYU SONG; LISA M. JUNGBAUER; MARY J. LADU; MARIANO BISBAL; ALFREDO LORENZO; JIYAN MA; PABLO R. HELGUERA; GERARDO A. MORFINI; SCOTT T. BRADY; GUSTAVO F. PIGINO

PLOS ONE

PUBLIC LIBRARY SCIENCE

Lugar: San Francisco; Año: 2017

1932-6203

<!-- /* Font Definitions */@font-face{font-family:Arial;panose-1:2 11 6 4 2 2 2 2 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536859905 -1073711037 9 0 511 0;}@font-face{font-family:"Cambria Math";panose-1:2 4 5 3 5 4 6 3 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face{font-family:"Arial Unicode MS";panose-1:2 11 6 4 2 2 2 2 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-134238209 -371195905 63 0 4129279 0;} /* Style Definitions */p.MsoNormal, li.MsoNormal, div.MsoNormal{mso-style-unhide:no;mso-style-parent:"";margin:0cm;margin-bottom:.0001pt;mso-pagination:widow-orphan;font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Arial Unicode MS";border:none;mso-ansi-language:EN-US;}p.Cuerpo, li.Cuerpo, div.Cuerpo{mso-style-name:Cuerpo;mso-style-unhide:no;mso-style-parent:"";margin:0cm;margin-bottom:.0001pt;mso-pagination:widow-orphan;font-size:11.0pt;font-family:Helvetica;mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS";color:black;border:none;mso-ansi-language:ES-TRAD;}span.Ninguno{mso-style-name:Ninguno;mso-style-unhide:no;mso-style-parent:"";mso-ansi-language:ES-TRAD;}.MsoChpDefault{mso-style-type:export-only;mso-default-props:yes;font-size:10.0pt;mso-ansi-font-size:10.0pt;mso-bidi-font-size:10.0pt;mso-fareast-font-family:"Arial Unicode MS";border:none;}.MsoPapDefault{mso-style-type:export-only;}@page WordSection1{size:612.0pt 792.0pt;margin:72.0pt 90.0pt 72.0pt 90.0pt;mso-header-margin:36.0pt;mso-footer-margin:36.0pt;mso-paper-source:0;}div.WordSection1{page:WordSection1;}-->Priondiseases include a number of progressive neuropathies involving conformational changes in cellular prion protein (PrPc)that may be fatal sporadic, familial or infectious. Pathological evidence indicated that neurons affected in priondiseases follow a dying-back pattern of degeneration. However, specificcellular processes affected by PrPc thatexplain such a pattern have not yet been identified. Results from cell biological and pharmacological experiments inisolated squid axoplasm and primary cultured neurons reveal inhibition of fastaxonal transport (FAT) as a novel toxic effect elicited by PrPc.Pharmacological, biochemical and cell biological experiments further indicate thistoxic effect involves casein kinase 2 (CK2) activation, providing a molecularbasis for the toxic effect of PrPc on FAT. CK2 was found to phosphorylateand inhibit light chain subunits of the major motor protein conventionalkinesin. Collectively, these findings suggest CK2 as a novel therapeutic targetto prevent the gradual loss of neuronal connectivity that characterizes priondiseases.